{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T22:40:33Z","timestamp":1775774433724,"version":"3.50.1"},"reference-count":50,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,7,10]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate asthma characteristics and treatment patterns, including short-acting \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -agonist (SABA) prescriptions, in primary and specialist care in the Singapore cohort of the SABA use IN Asthma (SABINA III) study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional, observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Multicentre study conducted at five sites across Singapore.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In patients with asthma (aged \u226512 years), data on demographics, disease characteristics and asthma treatment prescriptions were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by 2017 Global Initiative for Asthma recommendations) and practice type (primary\/specialist care).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 205 patients analysed (mean (SD) age, 53.6 (16.8) years; female, 62%), 55.9% were enrolled by specialists and 44.1% by primary care physicians. Most study patients (80.5%) had moderate-to-severe asthma (86.0% in specialist care and 74.4% in primary care). In the 12 months before study enrolment, 18.0% of patients experienced \u22651 severe exacerbation. Asthma was well or partly controlled in 78.0% of patients. Overall, 17.1% of all patients were overprescribed SABA (\u22653\u2009SABA canisters\/year) in the preceding 12 months, and overprescription was greater in specialist versus primary care (26.3% vs 5.6%). Only 2.9% of patients were prescribed SABA monotherapy, while 41.0% received SABA in addition to maintenance therapy. Among the latter, 40.5% were overprescribed SABA. Overall, a higher percentage of patients prescribed \u22653\u2009SABA canisters (vs 0\u20132 SABA canisters) were assessed as having uncontrolled asthma during the study visit (42.9% vs 17.6%). Maintenance therapy in the form of inhaled corticosteroids (ICS) or ICS\/long-acting \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      agonist fixed-dose combinations were prescribed to 14.1% and 84.9% of patients, respectively, in the 12 months before enrolment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this Singapore cohort, ~17% of all patients and more than 40% of patients prescribed SABA in addition to maintenance therapy were overprescribed SABA. These findings emphasise the need to align clinical practices with the latest evidence-based treatment recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT03857178\">NCT03857178<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064245","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T22:30:19Z","timestamp":1718058619000},"page":"e064245","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["SABA prescriptions and asthma management practices in Singapore: results from a cross-sectional, observational SABINA III study"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03857178","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"given":"David Hsien Yung","family":"Tan","sequence":"first","affiliation":[{"name":"National University Polyclinics, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tze Lee","family":"Tan","sequence":"additional","affiliation":[{"name":"Edinburgh Clinic, Singapore"},{"name":"Duke-NUS Medical School, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1114-4133","authenticated-orcid":false,"given":"Wee Hian","family":"Tan","sequence":"additional","affiliation":[{"name":"Pioneer Polyclinic, National University Polyclinics, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Choong","sequence":"additional","affiliation":[{"name":"AstraZeneca Singapore Pte Ltd, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J H I","family":"Beekman","sequence":"additional","affiliation":[{"name":"AstraZeneca, The Hague, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne Huiyi","family":"Khor","sequence":"additional","affiliation":[{"name":"National University Polyclinics, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Suraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Drs. Bain & Partners, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine Ruining","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9464-0476","authenticated-orcid":false,"given":"Hui Fang","family":"Lim","sequence":"additional","affiliation":[{"name":"Medicine, National University Hospital, Singapore"},{"name":"National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"2025121510032158000_14.6.e064245.1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5415\/apallergy.2014.4.2.75","article-title":"Epidemiology of adult asthma in Asia: toward a better understanding","volume":"4","author":"Song","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"2025121510032158000_14.6.e064245.2","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2013.5.5.251"},{"key":"2025121510032158000_14.6.e064245.3","unstructured":"National Health Survey . Ministry of Health. 2010. Available: https:\/\/www.moh.gov.sg\/docs\/librariesprovider5\/resources-statistics\/reports\/nhs2010---low-res.pdf [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.4","unstructured":"Global Burden of Disease . Institute for health Metrics and evaluation. 2019. Available: https:\/\/vizhub.healthdata.org\/gbd-compare\/ [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.5","unstructured":"The Economist Intelligence Unit Healthcare . Health outcomes and cost: a 166-country comparison. 2014. Available: www.eiu.com\/public\/topical_report.aspx?campaignid=Healthoutcome2014 [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.47102\/annals-acadmedsg.V46N3p81","article-title":"Asthma in Singapore: past, present and future","volume":"46","author":"Koh","year":"2017","journal-title":"Ann Acad Med Singap"},{"key":"2025121510032158000_14.6.e064245.7","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12137"},{"key":"2025121510032158000_14.6.e064245.8","first-page":"93","article-title":"Time for a new language for asthma control: results from REALISE Asia","volume":"8","author":"Price","year":"2015","journal-title":"J Asthma Allergy"},{"key":"2025121510032158000_14.6.e064245.9","doi-asserted-by":"publisher","DOI":"10.1159\/000338998"},{"key":"2025121510032158000_14.6.e064245.10","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-13-15","article-title":"The association between asthma control, health care costs, and quality of life in France and Spain","volume":"13","author":"Doz","year":"2013","journal-title":"BMC Pulm Med"},{"key":"2025121510032158000_14.6.e064245.11","unstructured":"Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention. 2022, Available: https:\/\/ginasthma.org\/ [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01444-5"},{"key":"2025121510032158000_14.6.e064245.13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.08.014","article-title":"The impact of inappropriate use of short acting beta agonists in asthma","volume":"131","author":"FitzGerald","year":"2017","journal-title":"Respir Med"},{"key":"2025121510032158000_14.6.e064245.14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01872-2019","article-title":"Overuse of short-acting \u03b22-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme","volume":"55","author":"Nwaru","year":"2020","journal-title":"Eur Respir J"},{"key":"2025121510032158000_14.6.e064245.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2012.08.014"},{"key":"2025121510032158000_14.6.e064245.16","unstructured":"Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention. 2019. Available: https:\/\/ginasthma.org\/ [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901963"},{"key":"2025121510032158000_14.6.e064245.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715274"},{"key":"2025121510032158000_14.6.e064245.19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01858-2019","article-title":"SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting \u03b22-agonist use in asthma","volume":"55","author":"Cabrera","year":"2020","journal-title":"Eur Respir J"},{"key":"2025121510032158000_14.6.e064245.20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01402-2021","article-title":"Short-acting \u03b22-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study","volume":"59","author":"Bateman","year":"2022","journal-title":"Eur Respir J"},{"key":"2025121510032158000_14.6.e064245.21","unstructured":"Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention. 2017. Available: https:\/\/ginasthma.org\/ [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-060ST"},{"key":"2025121510032158000_14.6.e064245.23","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01233-0"},{"key":"2025121510032158000_14.6.e064245.24","unstructured":"World Health Organization . The Asia-Pacific perspective: redefining obesity and its treatment. 2000. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/206936 [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.25","unstructured":"Royal College of Physicians . National review of asthma deaths (NRAD). Why asthma still kills. 2015. Available: https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/why-asthma-still-kills [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-033OC"},{"key":"2025121510032158000_14.6.e064245.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00188-2015"},{"key":"2025121510032158000_14.6.e064245.28","unstructured":"Singapore National Asthma Program . Primary care pages. Available: https:\/\/www.primarycarepages.sg\/patient-care\/chronic-disease-management\/singapore-national-asthma-programme-(snap) [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.47102\/annals-acadmedsg.V37N2p114","article-title":"Impact of the Singapore National Ssthma Program (SNAP) on preventor-reliever prescription ratio in polyclinics","volume":"37","author":"Chong","year":"2008","journal-title":"Ann Acad Med Singap"},{"key":"2025121510032158000_14.6.e064245.30","unstructured":"Healthcare schemes and subsidies. Ministry of health Singapore. Available: https:\/\/www.moh.gov.sg\/cost-financing\/healthcare-schemes-subsidies [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62693-2"},{"key":"2025121510032158000_14.6.e064245.32","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A067"},{"key":"2025121510032158000_14.6.e064245.33","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-6-14","article-title":"Lack of insurance coverage and urgent care use for asthma: a retrospective cohort study","volume":"6","author":"Markovitz","year":"2006","journal-title":"BMC Public Health"},{"key":"2025121510032158000_14.6.e064245.34","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/02770903.2019.1640730","article-title":"Cost barriers to asthma care by health insurance type among children with asthma","volume":"57","author":"Pate","year":"2020","journal-title":"J Asthma"},{"key":"2025121510032158000_14.6.e064245.35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/02770903.2018.1523929","article-title":"Gaps in health insurance coverage and emergency department use among children with asthma","volume":"56","author":"Gushue","year":"2019","journal-title":"J Asthma"},{"key":"2025121510032158000_14.6.e064245.36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1081-1206(10)60590-X","article-title":"Insurance status and asthma-related health care utilization in patients with severe asthma","volume":"100","author":"Peters","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025121510032158000_14.6.e064245.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000654","article-title":"Economic burden of asthma in Singapore","volume":"8","author":"Finkelstein","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2025121510032158000_14.6.e064245.38","first-page":"1386","article-title":"Management of asthma at private pharmacies in India","volume":"10","author":"Van Sickle","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121510032158000_14.6.e064245.39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40267-021-00855-w","article-title":"Cost-effectiveness analysis of Budesonide\/Formoterol (Symbicort\u00ae) as needed for mild asthma in Malaysia","volume":"37","author":"Raja Gopal","year":"2021","journal-title":"Drugs Ther Perspect"},{"key":"2025121510032158000_14.6.e064245.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-028995","article-title":"Understanding Reliever Overuse in patients purchasing over-the-counter short-acting Beta(2) agonists: an Australian community Pharmacy-based survey","volume":"9","author":"Azzi","year":"2019","journal-title":"BMJ Open"},{"key":"2025121510032158000_14.6.e064245.41","first-page":"312","article-title":"Factors influencing family physicians' drug prescribing behaviour in asthma management in primary care","volume":"50","author":"Tan","year":"2009","journal-title":"Singapore Med J"},{"key":"2025121510032158000_14.6.e064245.42","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jaip.2020.03.013","article-title":"Usage patterns of short-acting \u03922-Agonists and inhaled corticosteroids in asthma: A targeted literature review","volume":"8","author":"Amin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121510032158000_14.6.e064245.43","doi-asserted-by":"crossref","unstructured":"Azzi E , Kritikos V , Price D , et al . Reliever overuse when treatable traits go untreated. ERS International Congress 2019 abstracts; September 28, 2019:suppl doi:10.1183\/13993003.congress-2019.OA5151","DOI":"10.1183\/13993003.congress-2019.OA5151"},{"key":"2025121510032158000_14.6.e064245.44","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-021-00231-1","article-title":"The prevalence and outcome of short-acting \u03b22-agonists overuse in asthma patients in Taiwan","volume":"31","author":"Wang","year":"2021","journal-title":"NPJ Prim Care Respir Med"},{"key":"2025121510032158000_14.6.e064245.45","unstructured":"National strategic action plan on antimicrobial resistance. Singapore. 2017. Available: https:\/\/rr-asia.woah.org\/wp-content\/uploads\/2020\/03\/singapore_singapore-national-strategic-action-plan-on-amr.pdf [Accessed 10 Dec 2022]."},{"key":"2025121510032158000_14.6.e064245.46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.47102\/annals-acadmedsg.V37N2p89","article-title":"Bridging the gap between primary and specialist care: formidable challenges ahead","volume":"37","author":"Koh","year":"2008","journal-title":"Ann Acad Med Singap"},{"key":"2025121510032158000_14.6.e064245.47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12325-022-02356-2","article-title":"Safety of SABA monotherapy in asthma management: a systematic review and meta-analysis","volume":"40","author":"Sriprasart","year":"2023","journal-title":"Adv Ther"},{"key":"2025121510032158000_14.6.e064245.48","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1513\/AnnalsATS.201309-300RM","article-title":"Quality standards for real-world research. focus on observational database studies of comparative effectiveness","volume":"11 Suppl 2","author":"Roche","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2025121510032158000_14.6.e064245.49","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3283292207"},{"key":"2025121510032158000_14.6.e064245.50","doi-asserted-by":"crossref","unstructured":"Bateman ED , Price DB , Wang H-C , et al . Late breaking abstract - reimbursement for asthma care is a universal barrier to achieving asthma symptom control: the SABINA III study. ERS International Congress 2020 abstracts; September 7, 2020:suppl doi:10.1183\/13993003.congress-2020.2665","DOI":"10.1183\/13993003.congress-2020.2665"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:03:29Z","timestamp":1765821809000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bmjopen-2022-064245"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064245","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}